0001683168-22-008045.txt : 20221230 0001683168-22-008045.hdr.sgml : 20221230 20221128083300 ACCESSION NUMBER: 0001683168-22-008045 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20221128 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CNS Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001729427 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 822318545 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 2100 WEST LOOP SOUTH STREET 2: SUITE 900 CITY: HOUSTON STATE: TX ZIP: 77027 BUSINESS PHONE: 1-800-946-9185 MAIL ADDRESS: STREET 1: 2100 WEST LOOP SOUTH STREET 2: SUITE 900 CITY: HOUSTON STATE: TX ZIP: 77027 CORRESP 1 filename1.htm

CNS Pharmaceuticals, Inc.

2100 West Loop South, Suite 900

Houston, TX 77027

November 28, 2022

VIA EDGAR

U.S. Securities and Exchange Commission

Division of Corporate Finance

Washington, DC 20549

Attention: Doris Stacey Gama

Re:

CNS Pharmaceuticals, Inc.

Registration Statement on Form S-1

Registration No. 333-267975

Ladies and Gentlemen:

Pursuant to Rule 461 of the Securities Act of 1933, as amended, CNS Pharmaceuticals, Inc., a Nevada corporation (the “Company”), hereby respectfully requests that the effective date for the Registration Statement referred to above be accelerated so that it will be declared effective at 1:00 P.M. (Eastern Time) on November 29, 2022, or as soon thereafter as possible on such date.

	Very truly yours, CNS Pharmaceuticals, Inc.



	By:	/s/Christopher Downs
		Name: Christopher Downs Title: Chief Financial Officer